{"name":"eyeDNA Therapeutics","slug":"eyedna-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5OS051b2VwWDhmWFBMcE8yWTRWWGlyaElNOUtpSjZrdV9UekFPaDY3RW1rVjlIZjVkeXJPVl9kYno4eWxUOWVuV2ZWNnBvZ20wcTlFWDc1dDBLVUJjOWJ3eFdVdXBKRzJmQURHZDUzb2dJT3hMVHczVw?oc=5","date":"2025-11-24","type":"pipeline","source":"Pharma Voice","summary":"What’s next in the eye disease pipeline? - Pharma Voice","headline":"What’s next in the eye disease pipeline?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNSjRSX2xFc0t1LVNIM1h1LW9ZQVZabjRWa2lxSVY2WkV0WGdwRlJqM3RkclpWWl8tdDdEUjRlTUxBV2prVjNiTjZVbWFaR210bS1WQlJhcDJ3UnRrRGdUTmJqal93VW5xci1WNEh1am0zUVVIcThVdVVaa3VMTVVvQ0duTzY?oc=5","date":"2025-11-19","type":"trial","source":"Yahoo Finance","summary":"Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight - Yahoo Finance","headline":"Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPLTN2MDFDQkNKLVlRZW5LV3I2N1JnSHBSbVQ1NGhoeE9JNkFXZGxSUFFBT0w3cFZvTi1SUnZOYVdkanRhS0tfNEJVSDJTRWZpNmg3d3FTcWZBOHhxLXphRlJSUVBKUndoR09qZktpSE1fdjRLY184ZWZxTkc0TWQxaldzT0N3bEp3ZDRES3VB?oc=5","date":"2024-05-07","type":"trial","source":"pharmaphorum","summary":"eyeDNA plans pivotal trial of retinitis pigmentosa therapy - pharmaphorum","headline":"eyeDNA plans pivotal trial of retinitis pigmentosa therapy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}